Recent advances in the treatment of follicular lymphoma

被引：0
作者：
Yukio Kobayashi
机构：
[1] National Cancer Center Hospital,Hematology Division
来源：
International Journal of Clinical Oncology | 2009年 / 14卷
关键词：
Follicular lymphoma; CD20; CD22; Radioimmmunotherapy; New agent study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The success of anti-CD20 monoclonal antibody therapy for follicular lymphoma has encouraged efforts to identify new target molecules, and a new generation of more potent antibodies is now being developed, targeting either CD20 or other molecules. At the same time, other agents that were developed to treat other kinds of malignancies have turned out to be effective against this disease. In both treatment approaches, using either antibodies or chemical compounds, data on such trials are accumulating. In this mini-review these agents are introduced, and it is noted that clinical trials of these new agents are also ongoing in Japan.
引用
收藏
页码：191 / 196
页数：5
相关论文
共 95 条
  • [1] Levy R.(2008)New immunologic treatment for lymphoma Ann Oncol 19 129-142
  • [2] Houot R.(2008)Vaccines for lymphomas: idiotype vaccines and beyond Blood Rev 23 137-5495
  • [3] Brody J.(2008)First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 111 5486-219
  • [4] Czerwinski D.(2005)Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in J Immunother 28 212-2878
  • [5] Houot R.(2004)Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma Clin Cancer Res 10 2868-62
  • [6] Levy R.(2008)New monoclonal antibodies for non-Hodgkin’s lymphoma Ann Oncol 19 iv 60-2654
  • [7] Hagenbeek A.(2006)Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood 108 2648-5623
  • [8] Gadeberg O.(2006)Novel third generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction Blood 108 229a-424
  • [9] Johnson P.(2007)Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 5616-1223
  • [10] Vugmeyster Y.(2009)Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma Ann Oncol 20 413-3713
12345678910